Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $38.27M
• Dividend Yield: N/A
• Average Volume (3M): 83.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 1.19%
• EPS Growth: 61.65%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -2.77
• Shares Outstanding: 8,639,904
• 10 Day Avg. Volume: 91,865
• 30 Day Avg. Volume: 83,201
• PEG Ratio: -0.40
• Price to Book (P/B): -2.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.30
• Enterprise Value/Market Cap: 2.33
• Enterprise Value/Revenue: 0.15
• Enterprise Value/Gross Profit: 0.65
• Enterprise Value/Ebitda: -0.46
• 1Y Price Target: $21.60
• Price Target Upside: 392.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 38 Underperform
• Price Target: $4.00 ▼(-8.88%Downside)

Karyopharm Therapeutics' overall stock score is mainly impacted by its poor financial performance, including declining revenues, negative equity, and cash flow challenges. Technical analysis indicates a bearish trend, further weighing down the score. Valuation metrics are also weak, with a negative P/E ratio and no dividend yield, reflecting the speculative nature of the stock. The promising clinical trial developments and potential market opportunities were noted but did not significantly offset the financial and technical weaknesses.

Positive Factors

Clinical Trials

KPTI's ongoing Phase III SENTRY study for myelofibrosis has passed its futility analysis and enrolled approximately 80% of the target population.

Market Opportunities

Karyopharm estimates a peak revenue opportunity of $1 billion for Xpovio in myelofibrosis.

Regulatory Designations

Xpovio previously received FDA Fast Track Designation for the treatment of patients with myelofibrosis.

Negative Factors

Operational Challenges

Analysts remain on the sidelines, awaiting more durable growth trends on Xpovio sales and convincing evidence that sales growth will not be overshadowed by existing operating expenses.

Revenue Adjustments

Xpovio net product revenue in 2024 was impacted by higher gross-to-net adjustments, driven primarily by increased 340B discounts and Medicare rebates.

Revenue Performance

KPTI reported net product revenue of $21.1M for Xpovio, which was below consensus estimates and down approximately 28% from the previous quarter.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the commercialization of its approved drug, XPOVIO, which is marketed for specific cancer indications. Revenue streams include sales of the drug in the United States and potentially from licensing agreements and collaborations with other pharmaceutical companies for distribution outside the U.S. The company may also earn revenue from research and development collaborations, milestone payments, and royalties from its partners. Additionally, Karyopharm could receive funding from grants or government contracts to support its research initiatives, although the primary source of revenue remains the sale of its approved oncology products.

Karyopharm Therapeutics Financial Statement Overview

Summary

Karyopharm Therapeutics faces significant financial challenges, including declining revenues, consistent losses, negative equity, and cash flow issues. The high level of debt and negative margins present substantial risks, while reliance on external financing highlights the company's need for careful financial management to sustain operations.

Income Statement

Karyopharm Therapeutics has experienced a significant decline in revenue over the past few years, with the most recent year showing a slight decrease in revenue from $146.0 million to $145.2 million. The company consistently reports negative net income, with a net profit margin of -52.6% for the latest year, indicating challenges in achieving profitability. Additionally, the EBIT and EBITDA margins are negative, reflecting operating inefficiencies and high costs relative to revenue.

Balance Sheet

The company faces a challenging financial structure with negative stockholders' equity, indicating liabilities far exceed assets, and a debt-to-equity ratio that is not meaningful due to negative equity. The equity ratio is also negative, suggesting very high financial risk. There is a high level of total debt, which could pose significant risks if not managed properly.

Cash Flow

Karyopharm's cash flow from operations is negative, and free cash flow is also negative, which indicates difficulties in generating cash to cover operations and investments. However, there is a noticeable increase in financing cash flow, suggesting reliance on external funding. The free cash flow growth rate is negative, further emphasizing cash flow challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
142.13M	145.24M	146.03M	157.07M	209.82M	108.08M
	Gross Profit
136.64M	139.23M	141.09M	151.86M	206.42M	105.38M
	EBIT
-118.94M	-119.44M	-129.54M	-142.20M	-98.27M	-171.85M
	EBITDA
-40.54M	-38.60M	-118.42M	-139.31M	-96.98M	-167.85M
	Net Income Common Stockholders
-62.52M	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
260.38M	108.71M	191.44M	277.97M	228.62M	273.45M
	Total Assets
325.80M	164.42M	240.44M	358.17M	305.31M	313.05M
	Total Debt
178.59M	194.52M	177.02M	172.98M	169.29M	117.93M
	Net Debt
94.53M	132.05M	124.78M	37.79M	-21.17M	32.01M
	Total Liabilities
370.97M	350.44M	376.64M	374.83M	384.98M	262.50M
	Stockholders Equity
-45.17M	-186.02M	-136.21M	-16.66M	-79.67M	50.55M
Cash Flow		Free Cash Flow
-122.69M	-127.63M	-92.72M	-149.67M	-112.83M	-160.38M
	Operating Cash Flow
-122.75M	-127.49M	-92.72M	-149.55M	-107.12M	-160.23M
	Investing Cash Flow
88.82M	95.47M	7.94M	-104.26M	141.84M	-53.69M
	Financing Cash Flow
41.65M	41.65M	1.12M	193.74M	73.65M	172.08M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Negative. The current price of 4.39 is below the 20-day moving average (MA) of 4.60, below the 50-day MA of 5.02, and below the 200-day MA of 9.15, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 42.18 is Neutral, neither overbought nor oversold. The STOCH value of 39.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
CNTB	49 Neutral	$44.00M	―	-58.89%	―	―	―
XFOR	44 Neutral	$20.61M	1.59	121.75%	―	―	―
HOWL	44 Neutral	$59.68M	―	-82.81%	―	-92.95%	-50.02%
PEPG	40 Underperform	$49.08M	―	-75.45%	―	―	14.06%
KPTI	38 Underperform	$38.27M	―	41.08%	―	1.19%	61.65%
CAMP		$35.48M	―		―	―	―

Karyopharm Therapeutics Corporate Events

Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment

At the 2025 Annual Meeting of Stockholders held on May 28, Karyopharm Therapeutics Inc. announced that its stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available by 450,000. Additionally, Garen G. Bohlin and Zhen Su were elected as Class III directors for a three-year term. The stockholders also approved the compensation of the company’s named executive officers and recommended annual advisory votes on this compensation. Furthermore, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (KPTI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.